Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work

Sanofi is funneling €2.5 million into French clinical trial simulation specialist Novadiscovery as it looks to beef up its COVID-19 trial response.

Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.